Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC.

Cells - 1 Feb 2026

Živić Katarina, Boljević Ivana, Nedeljković Milica, Matović Milana, Janković Radmila, Tanić Miljana

Abstract excerpt

Ovarian cancer is a highly lethal disease. Tumors with a deficiency in the homologous recombination repair pathway (HRD) resulting from mutations in BRCA1/2 genes have a favorable response to platinum-based chemotherapy and targeted therapy with PARP inhibitors (PARPi) mediated by synthetic lethality. Promoter methylation of BRCA1/2 genes was previously associated with HRD, but little is known about whether it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to BRCA2 gene

Share to Mutation

Share to Ovarian Neoplasms

Share to Promoter Regions, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 41677640
DOI: 10.3390/cells15030277
PMCID: PMC12897218

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC.PMID 41677640Read ↗

Clinical utility of HRR gene methylation for predicting PARPi sensitivity in HGSOC patientsSemantic proximity Read ↗

Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.Semantic proximity Read ↗

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.Semantic proximity Read ↗

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity Read ↗

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)Semantic proximity Read ↗

Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer.Semantic proximity Read ↗

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaSemantic proximity Read ↗

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathwaysSemantic proximity Read ↗

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer RiskSemantic proximity Read ↗

<em>BRAC1</em> & <em>BRCA2</em> Methylation as a Prognostic and Predictive Biomarker in Cancer: Implementation in Liquid Biopsy in the Era of Precision MedicineSemantic proximity Read ↗

DNA methylation landscapes of matched primary and recurrent high grade serous ovarian cancers are preserved throughout disease progression and chemoresistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.